What is the Human Milk Oligosaccharides (HMO) market size and growth potential?
The global HMO market is projected to reach a staggering $850.5 million by 2030, growing at a CAGR of 20.1%. This explosive growth is fueled by the increasing awareness of HMOs' health benefits and their expanding applications beyond infant formula
What are the key benefits of HMOs for infants?
HMOs offer a range of benefits for infants, including supporting immune system development, promoting gut health, and potentially boosting cognitive development. They act as prebiotics, nourishing beneficial gut bacteria and helping protect against pathogens.
Who are the major players in the Human Milk Oligosaccharides (HMO) market?
Key players in the HMO market include Elicityl SA, Medolac Laboratories, Inbiose NV, Glycosyn, ZuChem, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, DuPont Nutrition & Health, and Nestlé Health Science.
Which is the fastest growing region in the Human Milk Oligosaccharides (HMO) Market?
Asia Pacific is the fastest-growing market share during the forecast period.